THERAPY-RELATED MYELODYSPLASTIC SYNDROME FOLLOWING CYCLOPHOSPHAMIDE PULSE AND/OR METHOTREXATE THERAPY IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS

HARUYO IWADATE; HIROKO KOBAYASHI; KIORI YANO; HIROSHI WATANABE; KAZUHIKO IKEDA; KAZUEI OGAWA; HIROMASA OHIRA

doi:10.5387/fms.56.121

Case Reports

THERAPY-RELATED MYELODYSPLASTIC SYNDROME FOLLOWING CYCLOPHOSPHAMIDE PULSE AND/OR METHOTREXATE THERAPY IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS

HARUYO IWADATE, HIROKO KOBAYASHI, KIORI YANO, HIROSHI WATANABE, KAZUHIKO IKEDA, KAZUEI OGAWA, HIROMASA OHIRA

Author information

Keywords: cyclophosphamide, therapy-related myelodysplastic syndrome, systemic lupus erythematosus

JOURNAL OPEN ACCESS

2010 Volume 56 Issue 2 Pages 121-127

DOI https://doi.org/10.5387/fms.56.121

Details

Abstract

A 27-year-old woman exhibited progressive pancytopenia during cyclophosphamide pulse therapy for lupus nephritis and low-dose methotrexate therapy for severe arthralgia. Bone marrow aspiration revealed highly abnormal cell morphology, indicating therapy-related myelodysplastic syndrome. Pancytopenia and bone marrow cell morphology improved 3 months after discontinuation of cyclophosphamide. It is necessary to promptly examine bone marrow cell morphology and chromosomal aberration in cases with connective tissue diseases complicated by sudden cytopenia during immunosuppressive therapy with chemotherapeutic agents.

Corresponding author

Register with J-STAGE for free!